Korean Journal of Psychosomatic Medicine (정신신체의학)

Korean Psychosomatic Society (한국정신신체의학회)
권호 표지
DOI QR코드

DOI QR Code

Association Between Psychiatric Medications and Urinary Incontinence

정신과 약물과 요실금의 연관성

  • Jaejong Lee (Department of Psychiatry, Veteran Health Service Medical Center) ;
  • SeungYun Lee (Department of Psychiatry, Veteran Health Service Medical Center) ;
  • Hyeran Ko (Department of Psychiatry, Veteran Health Service Medical Center) ;
  • Su Im Jin (Department of Psychiatry, Veteran Health Service Medical Center) ;
  • Young Kyung Moon (Department of Psychiatry, Veteran Health Service Medical Center) ;
  • Kayoung Song (Department of Psychiatry, Veteran Health Service Medical Center)
  • 이재종 (중앙보훈병원 정신건강의학과) ;
  • 이승윤 (중앙보훈병원 정신건강의학과) ;
  • 고혜란 (중앙보훈병원 정신건강의학과) ;
  • 진수임 (중앙보훈병원 정신건강의학과) ;
  • 문영경 (중앙보훈병원 정신건강의학과) ;
  • 송가영 (중앙보훈병원 정신건강의학과)
  • Received : 2023.11.28
  • Accepted : 2023.12.14
  • Published : 2023.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Urinary incontinence (UI), affecting 3%-11% of males and 25%-45% of females globally, is expected to rise with an aging population. It significantly impacts mental health, causing depression, stress, and reduced quality of life. UI can exacerbate psychiatric conditions, affecting treatment compliance and effectiveness. It is categorized into transient and chronic types. Transient UI, often reversible, is caused by factors summarized in the acronym DIAPPERS: Delirium, Infection, Atrophic urethritis/vaginitis, Psychological disorders, Pharmaceuticals, Excess urine output, Restricted mobility, Stool impaction. Chronic UI includes stress, urge, mixed, overflow, functional, and persistent incontinence. Drug-induced UI, a transient form, is frequently seen in psychiatric treatment. Antipsychotics, antidepressants, and other psychiatric medications can cause UI through various mechanisms like affecting bladder muscle tone, altering nerve reflexes, and inducing other conditions like diabetes or epilepsy. Specific drugs like lithium and valproic acid have also been linked to UI, though mechanisms are not always clear. Managing UI in psychiatric patients requires careful monitoring of urinary symptoms and judicious medication management. If a drug is identified as the cause, options include discontinuing, reducing, or adjusting the dosage. In cases where medication continuation is necessary, additional treatments like desmopressin, oxybutynin, trihexyphenidyl, or amitriptyline may be considered.

요실금의 유병률은 전세계적으로 남성에서 3~11%, 여성에서 25~45%에 달할 정도로 매우 흔한 질환이며, 향후 고령화 진행에 따라 요실금은 더욱 증가할 것으로 예상된다. 요실금은 환자와 가족의 삶의 질을 현저히 떨어뜨리고, 우울감, 스트레스, 자존감 저하를 유발한다. 기존에 정신과 질환을 앓고있는 환자에서 요실금이 새로 발생할 때 정신과적 증상 악화, 치료 순응도 저하, 치료 효과 반감 등에 영향을 줄 수 있어 유의가 필요하다. 요실금은 대부분 방광 저장능력의 결함으로 일과성, 만성 요실금으로 구분된다. 일과성 요실금은 가역적인 요실금으로 delirium, infection, atrophic urethritis/vaginitis, psychological disorders, pharmaceuticals, excess urine output, restricted mobility, stool impaction (DIAPPERS)이 대표적인 원인이다. 만성 요실금은 복압성, 절박, 혼합, 일류성 또는 범람, 기능성, 그리고 지속성 요실금으로 구분된다. 약물 유발 요실금은 일과성 요실금의 한 종류로 임상에서 흔히 볼 수 있으며 여러 가지 정신과 약제에 의해서도 유발될 수 있다. 항정신병 약제가 가장 대표적으로 알려졌으며, 비정형 항정신병 약제의 알파 아드레날린성 차단효과로 인한 요도 괄약근 근긴장도 저하, 항콜린성작용에 의한 요폐, 세로토닌 길항 효과로 인한 pudendal nerve 반사 저하, 심한 진정효과, 약물유발 당뇨, 경련 등 여러가지 메커니즘이 작용하는 것으로 추정된다. 리튬은 요실금과 관련된 증례가 보고된 사례는 미미하나 신성 요붕증으로 인한 일류성 요실금과 연관될 수 있고, 발프로산도 명확하지 않은 기전으로 야뇨증을 유발할 수 있다. 항우울제의 경우 SSRI는 세로토닌 경로와 배뇨근 활성에 영향을 줌으로써, SNRI와 TCA는 요저류를 유발함으로써 요실금을 일으킬 수 있다. 부프로피온과 멀타자핀도 드물지만 요실금 사례가 보고된 바 있다. 벤조디아제핀의 경우 방광의 근이완으로 요저류와 요실금을 모두 유발할 수 있으며 항치매제로 쓰이는 아세틸콜린 분해효소 억제제는 말초의 아세틸콜린을 증가시켜 요실금을 유발한다. 이렇듯 요실금은 여러 정신과 약제로 인하여 발생될 수 있으므로, 요로 증상을 면밀히 확인하여 약물 선택과 조절에 주의해야 하며, 요실금이 약물로 인한 것임이 밝혀졌을 경우 원인 약물의 중단, 감량 또는 분복 변경이 필요하며 약물치료로는 desmopressin, oxybutynin, trihexyphenidyl, amitriptyline을 추가해볼 수 있다.

Keywords

References

  1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A, Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-178. https://doi.org/10.1002/nau.10052
  2. Lee HS, Seo JT. Urinary incontinence and overactive bladder. Taehan Uihak Hyophoe Chi 2015;58:886.
  3. Nitti VW. The prevalence of urinary incontinence. Rev Urol 2001;3 Suppl 1(Suppl 1):S2-S6.
  4. Milsom I, Altman D, Cartwright R, Lapitan MC, Nelson R, Sillen U, Tikkinen K. Epidemiology of urinary incontinence (UI) and other lower urinary tract symptoms (LUTS), pelvic organ prolapse (POP) and anal incontinence (AI). In Incontinence: 5th International Consultation on Incontinence, Paris, February 2012. ICUD-EAU; p.15-107.
  5. Lee YS, Lee KS, Jung JH, Han DH, Oh SJ, Seo JT, Lee JG, Park HS, Choo MS. Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study. World J Urol 2011;29:185-190. https://doi.org/10.1007/s00345-009-0490-1
  6. Lee HY, Rhee Y, Choi KS. Urinary incontinence and the association with depression, stress, and self-esteem in older Korean Women. Sci Rep 2021;11:9054.
  7. Saarni SI, Harkanen T, Sintonen H, Suvisaari J, Koskinen S, Aromaa A, Lonnqvist J. The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. Qual Life Res 2006;15:1403-1414. https://doi.org/10.1007/s11136-006-0020-1
  8. Litwin MS, Saigal CS, Yano EM, Avila C, Geschwind SA, Hanley JM, Joyce GF, Madison R, Pace J, Polich SM, Wang M, Urologic Diseases in America Project. Urologic diseases in America Project: analytical methods and principal findings. J Urol 2005;173:933-937. https://doi.org/10.1097/01.ju.0000152365.43125.3b
  9. Sung W, You H, Yoon TY, Lee SJ. Socioeconomic costs of overactive bladder and stress urinary incontinence in Korea. Int Neurourol J 2012;16:23-29. https://doi.org/10.5213/inj.2012.16.1.23
  10. Anger JT, Saigal CS, Litwin MS, Urologic Diseases of America Project. The prevalence of urinary incontinence among community dwelling adult women: results from the National Health and Nutrition Examination Survey. J Urol 2006;175:601-604. https://doi.org/10.1016/S0022-5347(05)00242-9
  11. van Gerwen M, Schellevis F, Lagro-Janssen T. Comorbidities associated with urinary incontinence: a case-control study from the Second Dutch National Survey of General Practice. J Am Board Fam Med 2007;20:608-610. https://doi.org/10.3122/jabfm.2007.06.070151
  12. Manso M, Botelho F, Bulhoes C, Cruz F, Pacheco-Figueiredo L. Self-reported urinary incontinence in women is higher with increased age, lower educational level, lower income, number of comorbidities, and impairment of mental health. Results of a large, population-based, national survey in Portugal. World J Urol 2023;41:3657-3662. https://doi.org/10.1007/s00345-023-04677-5
  13. Drake MJ, Nixon PM, Crew JP. Drug-induced bladder and urinary disorders. Incidence, prevention and management. Drug Saf 1998;19:45-55. https://doi.org/10.2165/00002018-199819010-00004
  14. Tsakiris P, Oelke M, Michel MC. Drug-induced urinary incontinence. Drugs Aging 2008;25:541-549. https://doi.org/10.2165/00002512-200825070-00001
  15. Kashyap M, Tu LM, Tannenbaum C. Prevalence of commonly prescribed medications potentially contributing to urinary symptoms in a cohort of older patients seeking care for incontinence. BMC Geriatr 2013;13:57.
  16. Sun Y, Liu Y, Su T, Yuan J, Liu Z. Medical, epidemiologic, and social aspects of aging urinary incontinence questionnaire: study protocol for the translation and validation of a Chinese language version. Medicine 2019;98:e17719.
  17. Coyne KS, Kvasz M, Ireland AM, Milsom I, Kopp ZS, Chapple CR. Urinary incontinence and its relationship to mental health and health-related quality of life in men and women in Sweden, the United Kingdom, and the United States. Eur Urol 2012;61:88-95. https://doi.org/10.1016/j.eururo.2011.07.049
  18. Milsom I, Gyhagen M. The prevalence of urinary incontinence. Climacteric 2019;22:217-222. https://doi.org/10.1080/13697137.2018.1543263
  19. Lee KS, Sung HH, Na S, Choo MS. Prevalence of urinary incontinence in Korean women: results of a National Health Interview Survey. World J Urol 2008;26:179-185. https://doi.org/10.1007/s00345-008-0239-2
  20. Chang S, Kim H, Park HK, Kim HG, Palmer MH, Choi H. Prevalence and risk factors of male urinary incontinence: results of a Korean population-based study. Low Urin Tract Symptoms 2013;5:150-153. https://doi.org/10.1111/luts.12009
  21. Khandelwal C, Kistler C. Diagnosis of urinary incontinence. Am Fam Physician 2013;87:543-550.
  22. Kim HJ. Management of urinary incontinence in geriatric hospitals. Taehan Uihak Hyophoe Chi 2017;60:542.
  23. Korean continence society. Textbook of Voiding Dysfunction and Female Urology. 4th ed, Seoul:Koonja;2021.
  24. Jung HB, Kim HJ, Cho ST. A current perspective on geriatric lower urinary tract dysfunction. Korean J Urol 2015;56:266-275. https://doi.org/10.4111/kju.2015.56.4.266
  25. Irwin GM. Urinary incontinence. Prim Care 2019;46:233-242. https://doi.org/10.1016/j.pop.2019.02.004
  26. Keane DP, O'Sullivan S. Urinary incontinence: anatomy, physiology and pathophysiology. Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:207-226. https://doi.org/10.1053/beog.1999.0072
  27. Norton P, Brubaker L. Urinary incontinence in women. Lancet 2006;367:57-67. https://doi.org/10.1016/S0140-6736(06)67925-7
  28. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010;21:5-26. https://doi.org/10.1007/s00192-009-0976-9
  29. Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary incontinence in women: a review. JAMA 2017;318:1592-1604. https://doi.org/10.1001/jama.2017.12137
  30. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci 2008;9:453-466. https://doi.org/10.1038/nrn2401
  31. Dobrek L. Lower urinary tract disorders as adverse drug reactions-a literature review. Pharmaceuticals 2023;16:1031.
  32. Winkler D, Grohmann R, Friedrich M-E, Toto S, Bleich S, Seifert J, Konstantinidis A, Shariat SF, Kasper S, Pjrek E. Urological adverse drug reactions of psychotropic medication in psychiatric inpatients-a drug surveillance report from German-speaking countries. J Psychiatr Res 2021;144:412-420. https://doi.org/10.1016/j.jpsychires.2021.10.026
  33. Arasteh A, Mostafavi S, Zununi Vahed S, Mostafavi Montazeri SS. An association between incontinence and antipsychotic drugs: a systematic review. Biomed Pharmacother 2021;142:112027.
  34. Harrison-Woolrych M, Skegg K, Ashton J, Herbison P, Skegg DCG. Nocturnal enuresis in patients taking clozapine, risperidone, olanzapine and quetiapine: comparative cohort study. Br J Psychiatry 2011;199:140-144. https://doi.org/10.1192/bjp.bp.110.087478
  35. Herguner S, Mukaddes NM. Risperidone-induced double incontinence. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1085-1086. https://doi.org/10.1016/j.pnpbp.2008.02.007
  36. Duran A, Onder H, Ocak T, Yildirim O, Aslan S. High dose aripiprazole induced double incontinence. J Exp Clin Med 2014;30:361-362. https://doi.org/10.5835/jecm.omu.30.04.017
  37. Mendhekar DN, Duggal HS. Clozapine-induced double incontinence. Indian J Med Sci 2007;61:665-666. https://doi.org/10.4103/0019-5359.37788
  38. Vera PL, Miranda-Sousa A, Nadelhaft I. Effects of two atypical neuroleptics, olanzapine and risperidone, on the function of the urinary bladder and the external urethral sphincter in anesthetized rats. BMC Pharmacol 2001;1:4.
  39. Havens TH, Innamorato G, Nemec EC 2nd. Non-antipsychotic pharmacotherapy of psychogenic polydipsia: a system-atic review. J Psychosom Res 2021;152:110674.
  40. Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 2002;16:77-89. https://doi.org/10.2165/00023210-200216020-00001
  41. Hedges D, Jeppson K, Whitehead P. Antipsychotic medication and seizures: a review. Drugs Today 2003;39:551-557. https://doi.org/10.1358/dot.2003.39.7.799445
  42. Brocks DR. Anticholinergic drugs used in Parkinson's disease: an overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci 1999;2:39-46.
  43. Rosenbaum JF, Pollack MH. Treatment-emergent incontinence with lithium. J Clin Psychiatry 1985;46:444-445.
  44. Pattanayak RD, Rajhans P, Shakya P, Gautam N, Khandelwal SK. Lithium-induced polyuria and amiloride: Key issues and considerations. Indian J Psychiatry 2017;59:391-392. https://doi.org/10.4103/psychiatry.IndianJPsychiatry_168_17
  45. Azab AN, Shnaider A, Osher Y, Wang D, Bersudsky Y, Belmaker RH. Lithium nephrotoxicity. Int J Bipolar Disord 2015;3:28.
  46. Yamak WR, Hmaimess G, Makke Y, Sabbagh S, Arabi M, Beydoun A, Nasreddine W. Valproate-induced enuresis: a prospective study. Dev Med Child Neurol 2015;57:737-741. https://doi.org/10.1111/dmcn.12737
  47. Cheng W, Lin X, Lu D. Sodium valproate-induced enuresis in a pediatric bipolar patient. Neuropsychiatr Dis Treat 2013;9:1671-1672.
  48. DeMet EM, Sokolski KN. Sodium valproate increases pupillary responsiveness to a cholinergic agonist in responders with mania. Biol Psychiatry 1999;46:432-436. https://doi.org/10.1016/S0006-3223(99)00028-1
  49. Choonara IA. Sodium valproate and enuresis. Lancet 1985;1:1276.
  50. Zhang X, Lu W, Mo X. Sodium valproate-induced nocturnal enuresis in epilepsy: three case reports and a review of the literature. Front Neurol 2023;14:1104251.
  51. Sudan YS, Bansal AR. Urine incontinence induced by valproic acid. Indian J Pediatr 2017;84:867-868. https://doi.org/10.1007/s12098-017-2387-0
  52. Gosavi DD, Suman A, Jain M. Sodium valproate induced increased frequency of micturition and enuresis. Indian J Pharmacol 2013;45:87-88. https://doi.org/10.4103/0253-7613.106443
  53. Movig KLL, Leufkens HGM, Belitser SV, Lenderink AW, Egberts ACG. Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiol Drug Saf 2002;11:271-279. https://doi.org/10.1002/pds.705
  54. Tonini M, Candura SM. 5-HT4 receptor agonists and bladder disorders. Trends Pharmacol Sci 1996;17:314-316. https://doi.org/10.1016/0165-6147(96)81604-X
  55. Trinchieri M, Perletti G, Magri V, Stamatiou K, Montanari E, Trinchieri A. Urinary side effects of psychotropic drugs: a systematic review and metanalysis. Neurourol Urodyn 2021;40:1333-1348. https://doi.org/10.1002/nau.24695
  56. Li J, Yang L, Pu C, Tang Y, Yun H, Han P. The role of duloxetine in stress urinary incontinence: a systematic review and meta-analysis. Int Urol Nephrol 2013;45:679-686. https://doi.org/10.1007/s11255-013-0410-6
  57. Erdinc A, Gurates B, Celik H, Polat A, Kumru S, Simsek M. The efficacy of venlafaxine in the treatment of women with stress urinary incontinence. Arch Gynecol Obstet 2009;279:343-348. https://doi.org/10.1007/s00404-008-0729-x
  58. Sennfelt DAO, Marques da Silva MAR, Tavares AP da S. Bupropion in the treatment of major depressive disorder in real-life practice. Clin Drug Investig 2011;31 Suppl 1:19-24. https://doi.org/10.2165/1159617-S0-000000000-00000
  59. Izci F, Iris Koc M, Bilici R, Yalcin M, Bestepe EE. Urinary incontinence during sleep associated with extended release form of bupropion HCI. Case Rep Psychiatry 2015;2015:906294.
  60. Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998;51:267-285. https://doi.org/10.1016/S0165-0327(98)00224-9
  61. Oulis P, Leonardos A, Koulouris GC, Konstantakopoulos G. Mirtazapine-associated urinary retention. J Neuropsychiatry Clin Neurosci 2010;22:352o.e21-e352.e22. https://doi.org/10.1176/appi.neuropsych.22.3.352-o.e21
  62. Krhut J, Gartner M. [Urinary incontinence induced by the antidepressants-case report]. Ceska Gynekol 2015;80:65-68.
  63. Caksen H, Odabas D. Urinary retention due to Clonazepam in a child with dyskinetic cerebral palsy. J Emerg Med 2004;26:244.
  64. Landi F, Cesari M, Russo A, Onder G, Sgadari A, Bernabei R, Silvernet-HC Study Group. Benzodiazepines and the risk of urinary incontinence in frail older persons living in the community. Clin Pharmacol Ther 2002;72:729-734. https://doi.org/10.1067/mcp.2002.129318
  65. Lee HY, Li CC, Juan YS, Chang YH, Yeh HC, Tsai CC, Chueh KS, Wu WJ, Yang YH. Urinary incontinence in alzheimer's disease: a population-based cohort study in taiwan. Am J Alzheimers Dis Other Demen 2017;32:51-55. https://doi.org/10.1177/1533317516680900
  66. Hashimoto M, Imamura T, Tanimukai S, Kazui H, Mori E. Urinary incontinence: an unrecognised adverse effect with donepezil. Lancet 2000;356:568.
  67. Siegler EL, Reidenberg M. Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia. Clin Pharmacol Ther 2004;75:484-488. https://doi.org/10.1016/j.clpt.2004.01.015
  68. Rossom R, Adityanjee, Dysken M. Efficacy and tolerability of memantine in the treatment of dementia. Am J Geriatr Pharmacother 2004;2:303-312. https://doi.org/10.1016/j.amjopharm.2004.12.006
  69. Lampela P, Taipale H, Hartikainen S. Use of cholinesterase inhibitors increases initiation of urinary anticholinergics in persons with Alzheimer's disease. J Am Geriatr Soc 2016;64:1510-1512. https://doi.org/10.1111/jgs.14220
  70. Griebling TL. Urinary incontinence in the elderly. Clin Geriatr Med 2009;25:445-457. https://doi.org/10.1016/j.cger.2009.06.004
  71. Sarma S, Ward W, O'Brien J, Frost ADJ. Severe hyponatraemia associated with desmopressin nasal spray to treat clozapine-induced nocturnal enuresis. Aust N Z J Psychiatry 2005;39:949.